HEALTHY LIVING
BRAIN: OMEGA-6 FATTY ACIDS MAY FIGHT BIPOLAR DISORDER A study from the University of South
THE LATEST RESEARCH
May Boost Chemo, Protect Heart T
reating acute myeloid leukemia (AML), the most
common type of leukemia in adults, with chemotherapy can increase the risk of heart damage. Scientists at the University of Missouri School of Medicine found that AGTR1, a receptor responsible for cell reproduction, was overabundant in the blood cells of patients with leukemia. Further research in mice revealed that losartan, a common medicine that treats high blood pressure, restrained AGTR1, which disrupted cancer growth and slowed the development of leukemia. “When we treated mice with the AGTR1 inhibitor losartan, we observed that this commercially available drug shows great promise in reducing AML development while protecting against chemotherapy-induced cardiotoxicity,” said Xunlei Kang, M.D., Ph.D. “This
Blood Pressure Drug
CHEMO DRUGS CAN CAUSE SIGNIFICANT HEARING LOSS A study published in JAMA Oncology found that 78% of survivors of testicular cancer who received cisplatin-based chemotherapy experienced significant hearing loss. Cisplatin is commonly used to treat a variety of advanced cancers, including bladder, lung, neck, and testicular. Ears are particularly vulnerable to damage since they have little ability to filter out the drug, causing it to become trapped. This leads to inflammation and the destruction of sensory cells that are critical for hearing.
finding shows great potential to both enhance the success of chemotherapy while protecting the heart.”
Adding Chemo to Hormone Therapy Helps Control Prostate Cancer
C
ombining chemotherapy with hormonal therapy helps control prostate cancer in patients with disease that has spread beyond the prostate to nearby tissues,
according to a study published in the Journal of Urology. The patients, who were at increased risk for metastasis, were divided into two groups. One group was given both chemo and hormonal therapy before undergoing surgery, while the second group received only hormonal therapy. The cancer was reduced before surgery in 65% of patients receiving both therapies and in 48% of patients receiving only hormonal therapy. At three years of follow-up, 29% of patients receiving chemotherapy plus hormonal therapy remained free of rising prostate-specific antigen (PSA) levels compared to 9.5% with hormonal therapy only.
98 NEWSMAX MAXLIFE | OCTOBER 2024
Australia found that higher levels of lipids containing arachidonic acid, an omega-6 polyunsaturated fatty acid that occurs in seafood, eggs, and poultry, are linked to a lower risk for bipolar disorder. The study of 14,296 Europeans was published in Biological Psychiatry. “And conversely, those with lower levels of arachidonic acid had a higher risk for bipolar disorder,” said David Stacey, Ph.D.
LONGEVITY: LOW TESTOSTERONE LINKED WITH HIGHER DEATH RISK A meta-analysis of 11 studies published in Annals of Internal Medicine found that low testosterone in men (7.4 nmol/L) is associated with increased risk for all-cause mortality. Very low testosterone ( 5.3 nmol/L) was linked with an increased risk of cardiovascular death.
BREAST CANCER: BARIATRIC SURGERY LOWERS RISK Obese women who undergo bariatric
surgery lower their risk for developing breast cancer, according to a study published in JAMA Surgery. Women who underwent weight loss surgery lowered their risk by 32% when compared to a control group who underwent conventional obesity treatments. Women with high insulin levels before undergoing surgery lowered their risk even more — 52% — when compared to the control group.
SURGERY: FRAILTY PREDICTS SURGERY OUTCOMES IN OLDER ADULTS Frailty — weakness, weight loss, slowness, and other declines in function — is a significant predictor of how people aged 65 and older will fare after surgery. A study published in the journal Anaesthesia found that frail patients had higher mortality rates at 30 days and 365 days following surgery, and increased readmission rates at 30 days.
©ISTOCK
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108
